Retina Society 2024: First time phase 2 clinical trial results for ONL-1204 for ...
Durga Borkar, MD, discusses phase 2 clinical trial results for ONL-1204, a novel agent for rhegmatogenous retinal detachment, showing visual benefits for high-risk patients. The study involved intravitreal injections and surgical repair, with plans for subgroup analyses and FDA meetings.
Reference News
Retina Society 2024: First time phase 2 clinical trial results for ONL-1204 for ...
Durga Borkar, MD, discusses phase 2 clinical trial results for ONL-1204, a novel agent for rhegmatogenous retinal detachment, showing visual benefits for high-risk patients. The study involved intravitreal injections and surgical repair, with plans for subgroup analyses and FDA meetings.